Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jonathan Rich

Advanced Heart Failure and Transplant Cardiology Chicago, IL Medical Doctor

NPI 1467501064 CMS profile 247465

675 N Saint Clair St Ste 19-100, Chicago, IL 60611

Open in the dashboard

General payments

$327,464

223 records reported · program years 2019–2025

Research payments

$4,440

Paid to them · 5 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$45,776 paid to institutions, not to them · program years 2019–2023

Through program year 2025, Jonathan Rich of Chicago, IL is reported in the CMS Open Payments database as having received $327,464 across 223 general payments and $4,440 in research payments paid to them. Separately, studies naming them as principal investigator received $45,776 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Advanced Heart Failure and Transplant Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $50 2
2024 General $27,640 7
2023 General $7,018 5
2022 General $27,622 16
2021 General $58,772 41
2021 Research $1,425 2
2020 General $81,132 41
2020 Research $2,115 2
2019 General $125,229 111
2019 Research $900 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jonathan Rich
  • Advanced Heart Failure and Transplant Cardiology median
  • Middle half of Advanced Heart Failure and Transplant Cardiology
  • National median

In program year 2025, general payments to Jonathan Rich were reported at $50. Among 967 Advanced Heart Failure and Transplant Cardiology profiles paid that year, the median was $1,024 and the middle half received between $289 and $6,890.

Show as a table
Year Jonathan Rich Advanced Heart Failure and Transplant Cardiology median Middle half National median
2019 $125,229 $863 $224–$4,562 $163
2020 $81,132 $452 $122–$3,992 $114
2021 $58,772 $550 $159–$3,571 $132
2022 $27,622 $729 $221–$4,357 $149
2023 $7,018 $1,002 $309–$5,827 $160
2024 $27,640 $931 $273–$5,204 $164
2025 $50 $1,024 $289–$6,890 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $138,650 82 payments
  2. Lilly USA, LLC $51,231 28 payments
  3. Novartis Pharmaceuticals Corporation $46,468 26 payments
  4. Medtronic Vascular, Inc. $28,123 19 payments
  5. Eli Lilly and Company $19,800 8 payments
  6. Abbott Laboratories $19,075 51 payments
  7. Amgen Inc. $19,040 3 payments
  8. Merck Sharp & Dohme Corporation $2,750 1 payment
  9. Medtronic, Inc. $2,250 1 payment
  10. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $47 3 payments
  11. Other $29 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $210,109 81 payments
  2. Consulting Fee $75,607 32 payments
  3. Travel and Lodging $28,368 41 payments
  4. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $5,250 3 payments
  5. Compensation for serving as faculty or as a speaker for a medical education program $4,200 5 payments
  6. Food and Beverage $3,929 61 payments
Products named General payments · program years 2019–2025
  1. JARDIANCE Diabetes $96,535 65 payments
  2. JARDIANCE Diabetes $62,100 30 payments
  3. ENTRESTO $46,468 26 payments
  4. JARDIANCE Diabetes $27,340 6 payments
  5. HeartWare HVAD Ventricular Assist Devices $16,998 17 payments
  6. HeartMate 3 Left Ventricular Dev $6,829 24 payments
  7. CardioMEMS HF System Cardiac Arrhythmias and Heart Failure $5,250 3 payments
  8. TRADJENTA $5,000 2 payments
  9. CardioMEMS HF System Heart failure $4,200 5 payments
  10. HeartWare HVAD Ventricular Assist Devices $2,250 1 payment
  11. Other $2,930 25 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic Vascular, Inc. $3,015 3 payments
  2. Medtronic, Inc. $1,425 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 37 drugs

Part D claims

2,288

Median for Advanced Heart Failure and Transplant Cardiology: 1,489

Drug cost

$1,074,447

Median for Advanced Heart Failure and Transplant Cardiology: $885,869

Branded share of claims

19%

Median for Advanced Heart Failure and Transplant Cardiology: 32.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vyndamax Tafamidis Brand 16 $340,794
Entresto Sacubitril/Valsartan Brand 181 $239,774
Opsumit Macitentan Brand 13 $163,703
Eliquis Apixaban Brand 71 $109,767
Jardiance Empagliflozin Brand 79 $100,863
Ambrisentan Generic 16 $34,360
Xarelto Rivaroxaban Brand 19 $30,929
Tacrolimus Generic 94 $9,736
Tadalafil Generic 20 $6,168
Bumetanide Generic 137 $5,593

The 10 drugs with the highest cost, of 37 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 800 Part D prescribers listed as Advanced Heart Failure and Transplant Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$127,420

Medicare's payments for the services billed

Medicare patients

336

Average age 71

Services billed

1,378

149 women, 187 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 75%
Ischemic heart disease 72%
Chronic kidney disease 70%
Atrial fibrillation 54%
Diabetes 50%
Arthritis 46%
Depression 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $27,340
  • Lilly USA, LLC $300
$27,640 79 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

228 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Advanced Heart Failure and Transplant Cardiology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record